The Free Markets ETF

FMKT is an actively managed fund that aims to capitalize on US listed equities that are anticipated to benefit from regulatory shifts favoring free market dynamics. The fund targets sectors burdened by high regulation like healthcare, financial services, and energy, predicting regulatory relief. Investments also span technology and consumer goods sectors less affected by regulation. Examples of favorable shifts include deregulation, reduced taxes, licensing reforms, and tariffs elimination. The Fund seeks value by leveraging expected regulatory reforms, aiming to buffer against increased regulatory burdens. The selection process evaluates companies poised for deregulation benefits, focusing on their adaptability, strategies, and competitive positioning within industries. The portfolio generally consists of 25-50 positions, investing at least 80% in deregulation beneficiaries. Up to 5% may be invested in ETPs with exposure to Bitcoin and Ether, enhancing diversification and seizing digital asset growth opportunities.

The Free Markets ETF trades as FMKT on AMEX. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

The Free Markets ETF can be compared against peers such as Argent Focused Small Cap ETF, DoubleLine Fortune 500 Equal Weight ETF, Hedgeye Capital Allocation ETF, TrueShares Structured Outcome (March) ETF, Horizon Kinetics Medical ETF, iShares Nasdaq-100 ex Top 30 ETF.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $18.70M, beta of 0.93, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FMKT currently shows total debt of N/A and beta of 0.93. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: http://www.freemarketsetf.com/

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.